Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

7

Jul 2026

New review shows why antidepressants often fail in Alzheimer’s and Parkinson’s depression

A Molecular Psychiatry review shows that depression in Alzheimer’s and Parkinson’s disease may reflect disease-specific molecular, neurotransmitter, inflammatory, and circuit-level disruptions rather than standard depression biology alone. It argues that broad antidepressants often show limited efficacy in these patients and that future trials should use biomarkers, neuroimaging, and symptom profiling to guide targeted treatments.

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

7

Jul 2026

Updated ABCs framework gives clinicians a clearer path to prevent heart disease

A 2026 State-of-the-Art review updates the ABCs of cardiovascular disease prevention to help clinicians apply contemporary risk assessment, lifestyle, pharmacologic, and cardiometabolic strategies in routine care. The framework emphasizes PREVENT™ risk equations, Life’s Essential 8, CKM syndrome, obesity care, lipid lowering, blood pressure control, healthy aging, heart failure prevention, and atrial fibrillation management.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.